This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma.
| Condition | Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer, Breast Cancer, Cervical Cancer, Cholangiocarcinoma, Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Pleural Mesothelioma, Prostate Cancer, Sarcoma, Tongue Cancer, Thymic Carcinoma, Urinary Tract Cancer |
|---|---|
| Treatment | QBS10072S |
| Clinical Study Identifier | NCT04430842 |
| Sponsor | Quadriga Biosciences, Inc. |
| Last Modified on | 27 January 2023 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.